Listen to the episode on a streaming platform by clicking one of the links below:

• Listen on Spotify

• Listen on Apple Podcasts

• The cautious habits that shaped healthcare's first wave of AI adoption are increasingly working against health systems, and a new playbook is emerging from those navigating the shift in real time. Four hard truths now shape AI strategy for 2026:

  • You must deploy AI faster than feels safe. Legacy governance designed for episodic, bespoke review can't keep up with a portfolio of dozens of tools that update every few months. The fix isn't less rigor but proportional rigor—tiered review, pre-agreed decision rights, and standardized intake.

  • Your "human in the loop" is disappearing. Volume, speed, and automation bias have eroded the assumption that human review inherently protects against AI error. The work is shifting from supervising every action to designing systems where autonomy is safe by default: defining what AI can do independently, what it must escalate, and what it will never do, even when it could.

  • Soft ROI is no longer enough. Federal cuts, margin compression, and capital scrutiny have reset executive expectations. Most organizations see value but struggle to convert it into dollars, because the operational mechanism connecting AI to financial impact was never designed.

  • Ad hoc monitoring will not scale. As AI becomes enterprise infrastructure, oversight needs its own infrastructure to match. Leading systems are moving from bespoke supervision to industrialized oversight—Sutter Health's centralized platform approach to imaging AI and UW Health's tiered governance model both treat monitoring as lifecycle management rather than a favor clinicians perform on the side of their desks.

• A new rule finalized by CMS will overhaul the ACA marketplaces by expanding access to high deductible “catastrophic” plans and by allowing insurers to offer non-standard plans with different levels of cost sharing.

  • A combination of projected enrollment losses and thinner benefit designs will pressure both payer mix and patient collections for health systems.

  • While the Trump administration isn’t looking to repeal the ACA altogether, the full set of changes points towards a more conservative vision of healthcare coverage that partly resembles the pre-ACA status quo for individual insurance.

• This week's featured graphic tracks a fragile recovery in health system operating margins through Q1 2026—climbing from a median of -0.6% in January to 0.4% in March.

  • While revenue has rebounded, an accelerating trend in uncompensated care is worth watching over the longer term.

• CMS issued a six-month moratorium on Medicare enrollment for new home health and hospice providers as part of its broader fraud crackdown.

  • Existing providers aren't affected, but the policy could temporarily block ownership changes and prevent suspected operators from crossing state lines to evade enforcement.

  • Health systems aren't the direct target, but the moratorium could complicate discharge planning and shrink post-acute options. That could have knock-on effects for length-of-stay costs, value-based arrangements, and Hospital-at-Home or SNF-at-Home models.

Listen to the episode on a streaming platform by clicking one of the links below:

• Listen on Spotify

• Listen on Apple Podcasts

• Q1 earnings from the four largest publicly traded hospital operators—HCA, Tenet, UHS, and CHS—showed soft headline volumes, but the softness was a mix of one-offs (shorter flu season, winter storms) layered on top of the predicted decline due to the expiration of ACA enhanced premium tax credits.

  • The weather and respiratory effects are temporary, but the payer mix erosion from exchange losses is permanent and expected to worsen through 2026.

  • High-acuity outpatient migration is now the dominant capital story, with all four operators leaning hard into ASC acquisitions and de novos.

  • The most striking takeaway is what the calls didn't dwell on: OBBBA barely came up, even as many nonprofit health system boards have made it the dominant frame for 2026 strategy. The for-profits are betting that commercial mix and balance sheet strength make Medicaid policy impact less existential.

• UnitedHealthcare announced it will eliminate prior authorization for roughly 30% of services requiring advance approval by year-end—with an emphasis on outpatient services—paralleling similar pledges from other major payers as part of a voluntary commitment with HHS and CMS.

  • Whether this is substantive or PR depends on what's actually on the list, which has not yet been disclosed. A previously announced rural provider carve-out may matter more, given how much rural hospitals with thin margins stand to gain from reduced administrative burden.

  • By easing friction on outpatient services while leaving inpatient utilization management intact, UHC is widening the administrative gap between settings—sharpening the strategic pressure on health systems around ambulatory capacity and ASC investment, and giving physicians yet another reason to prefer working outside the hospital.

• CMS recently proposed CJR-X, a mandatory nationwide bundled payment model for lower extremity joint replacement taking effect October 1, 2027—extending the original CJR model’s two-sided risk structure to most IPPS hospitals.

  • The savings playbook still runs through post-acute spend, but the easy reductions have largely been harvested. CMS itself acknowledges this by trimming the target price discount from 3% to 2%. For systems where post-acute utilization has already structurally shifted, CJR-X is less a savings opportunity than a downward adjustment to LEJR economics they'll need to offset elsewhere.

  • Paired with TEAM, CJR-X signals that CMS has validated a template it's likely to keep using: mandatory episode pricing on high-volume, high-cost procedures, with regional benchmarks engineered to extract savings from whatever lever is available.

• Delays in HHS processing of J-1 visa waivers threaten to force hundreds of foreign-trained physicians out of the U.S. by a July 30 deadline, jeopardizing placements in designated provider shortage areas. The pressure compounds a separate $100K H-1B visa fee hike that has already caused 64% of AHA member hospitals to limit or pause foreign physician recruitment.

  • The impact will fall hardest on the systems least able to absorb it—rural providers, safety-net systems, and those with heavy Medicaid mix—and will worsen access in the specialties J-1 waivers are reserved for (primary care, pediatrics, OB/GYN, behavioral health), which also happen to be the upstream referral channels and relationship-builders that health systems can least afford to lose.

  • Advocacy and litigation are the likeliest paths to resolution, but neither moves quickly: three lawsuits and a bipartisan fee exemption bill are all stalled, and election-year politics make standalone action unlikely. The recent quiet reversal of the physician travel ban after coordinated pressure from AHA, AMA, NRHA, and state AGs offers a template—but only if stakeholders mobilize before the deadline.

• CMS Administrator Mehmet Oz directed all 50 state Medicaid directors to revalidate program providers, expanding a fraud crackdown that had previously focused on Democratic-led states.

  • Beyond the immediate compliance push, the initiative may also serve a broader narrative purpose: reinforcing concerns about Medicaid integrity in ways that could support future spending reductions.

  • The audits could squeeze the smaller partners health systems depend on, whose thinner margins and limited compliance infrastructure leave them more exposed.

Listen to the episode on a streaming platform by clicking one of the links below:

• Listen on Spotify

• Listen on Apple Podcasts

We dig into how St. Charles Health System, a four-hospital not-for-profit in Central Oregon and the sole major provider across a 32,000-square-mile service area, went from seven Medicare Advantage payers down to one and then turned a twenty-year track record of clinical quality into a negotiating tool that cut cancer treatment authorization times from weeks to a single day.

Matt Swafford, CFO, and Mark Hallett, Chief Clinical Officer, walk us through the decision to terminate contracts with six national MA payers, how they used NCCN concordance rates to negotiate instant authorization with PacificSource, and the CFO-CCO partnership model that enabled it all.